STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARQT
  4. [Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity

ARQT Form 4: EVP Burnett disposes 3,847 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Arcutis Biotherapeutics executive Patrick Burnett, the company's Executive Vice President and Chief Medical Officer, sold 3,847 shares of Arcutis common stock on 08/08/2025. The sales were made pursuant to a 10b5-1 trading plan adopted on 12/12/2024 with a plan end date of 02/27/2026. The filing reports a weighted-average sale price of $14.0339, with individual trade prices ranging from $13.992 to $14.12. After the reported transaction, Burnett directly beneficially owned 108,999 shares.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine 10b5-1 insider sale of 3,847 shares at $14.03; holding remains 108,999 — neutral to company valuation.

The Form 4 shows a small, disclosed sale executed under a pre-existing 10b5-1 plan, with a weighted-average price of $14.0339. The transaction is transparent: the filer notes the transaction price range and offers to provide per-trade details on request. There is no information in the filing indicating other compensatory or derivative exercises tied to this sale, and the reported remaining direct ownership is 108,999 shares. Given the limited size and planned nature of the sale, the direct investor impact appears neutral based solely on the disclosed facts.

TL;DR: Sale was executed under an established 10b5-1 plan; disclosure is clear and the filer commits to providing price-level details on request.

The filing documents that the sale was made under a 10b5-1 trading plan adopted on 12/12/2024 and set to end on 02/27/2026, which supports an affirmative defense for pre-planned trades. The report includes a weighted-average price ($14.0339) and an explicit range ($13.992–$14.12), and the filer notes willingness to supply granular transaction pricing if requested. From a governance and disclosure perspective, the filing is thorough and follows expected Form 4 practices; it does not present material governance concerns based on the provided content.

Insider Burnett Patrick
Role See Remarks
Sold 3,847 shs ($54K)
Type Security Shares Price Value
Sale Common Stock 3,847 $14.0339 $54K
Holdings After Transaction: Common Stock — 108,999 shares (Direct)
Footnotes (1)
  1. The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024 by the Reporting Person, with a plan end date of February 27, 2026. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.992 to $14.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Burnett Patrick
(Last) (First) (Middle)
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD, SUITE 300
(Street)
WESTLAKE VILLAGE CA 91361
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/08/2025 S(1) 3,847(1) D $14.0339(2) 108,999 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024 by the Reporting Person, with a plan end date of February 27, 2026.
2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.992 to $14.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Remarks:
Reporting Person's Title: Executive Vice President and Chief Medical Officer
/s/ Latha Vairavan, Attorney-in-Fact for Patrick Burnett 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What transaction did Patrick Burnett report on Form 4 for ARQT?

The Form 4 reports that Patrick Burnett sold 3,847 shares of Arcutis common stock on 08/08/2025 under a 10b5-1 trading plan.

At what price were the ARQT shares sold?

The filing reports a weighted-average sale price of $14.0339, with individual sale prices ranging from $13.992 to $14.12.

Was the sale by Burnett discretionary or under a trading plan?

The sale was executed pursuant to a 10b5-1 trading plan adopted on 12/12/2024 with a plan end date of 02/27/2026.

How many ARQT shares does Burnett own after the reported sale?

Following the reported transaction, Burnett directly beneficially owned 108,999 shares.

Does the filing offer more granular price details for the sales?

Yes. The reporting person states they will provide full information on the number of shares sold at each price within the disclosed range upon request.